Search Result

Results for "

dual modulator

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (2) Apoptosis (2) Cannabinoid Receptor (2) Carbonic Anhydrase (1) Casein Kinase (1) Caspase (1) FAAH (2) FXR (1) Glucocorticoid Receptor (2) Guanylate Cyclase (1) HSP (2) Isocitrate Dehydrogenase (IDH) (1) Lactate Dehydrogenase (1) mGluR (1) Mineralocorticoid Receptor (1) Opioid Receptor (1) PD-1/PD-L1 (1) Phosphatase (1) Phospholipase (1) PPAR (3) Sigma Receptor (1) TNF Receptor (1) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (1) Endocrinology (1) Infection (2) Inflammation/Immunology (4) Metabolic Disease (4) Neurological Disease (8)

By Targets:

5-HT Receptor (2)

Apoptosis (2)

Cannabinoid Receptor (2)

Carbonic Anhydrase (1)

Casein Kinase (1)

Caspase (1)

FAAH (2)

FXR (1)

Glucocorticoid Receptor (2)

Guanylate Cyclase (1)

HSP (2)

Isocitrate Dehydrogenase (IDH) (1)

Lactate Dehydrogenase (1)

mGluR (1)

Mineralocorticoid Receptor (1)

Opioid Receptor (1)

PD-1/PD-L1 (1)

Phosphatase (1)

Phospholipase (1)

PPAR (3)

Sigma Receptor (1)

TNF Receptor (1)

Toll-like Receptor (TLR) (1)

By Research Areas:

Cancer (6)

Cardiovascular Disease (1)

Endocrinology (1)

Infection (2)

Inflammation/Immunology (4)

Metabolic Disease (4)

Neurological Disease (8)

Inhibitors & Agonists

Inhibitory Antibodies

Targets Recommended: DYRK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-114863

PHCCC(4Me) THCCC	mGluR	Neurological Disease
PHCCC(4Me) (THCCC), a PHCCC analog, is a dual mGluR2 (IC₅₀ of 1.5 μM) negative allosteric modulator and mGluR3 (EC₅₀ of 8.9 μM) positive allosteric modulator .

HY-147361

LDCA	Apoptosis Lactate Dehydrogenase	Cancer
LDCA is a dual-hit metabolic modulator and inhibits LDH-A enzyme activity to stimulate apoptosis in the malignant population. LDCA can be used for the research of oncogenic progression .

HY-152254

CB2R/FAAH modulator-3	FAAH Cannabinoid Receptor	Infection Neurological Disease Inflammation/Immunology Cancer
CB2R/FAAH modulator-3 (compound 27) is a dual targeting modulator that acts as a CB2R agonist and FAAH inhibitor. The K_i values for CB2R/FAAH modulator-3 are 20.1 and 67.6 nM for CB2R and CB1R, respectively, and the IC₅₀ value for FAAH is 3.4 μM. CB2R/FAAH modulator-3 can be used in studies related to cancer, deleterious inflammatory cascades occurring in neurodegenerative diseases, and COVID-19 infection .

HY-170944

BAG3/HSP70-IN-1	HSP Apoptosis Caspase	Cancer
BAG3/HSP70-IN-1 (compound 16) is the first-in-class BAG3/HSP70 dual modulator. BAG3/HSP70-IN-1 inhibits HeLa cells with an IC₅₀ of 49.46 μM. BAG3/HSP70-IN-1 induces Apoptosis by activating caspase 3 and caspase 9 levels in HeLa cells. BAG3/HSP70-IN-1 elevates p21 levels while reduces FOXM1 expression in HeLa cells. BAG3/HSP70-IN-1 decreases ATPase activity .

HY-169964

TSPO/Carbonic Anhydrase Modulator 1	Carbonic Anhydrase	Neurological Disease
TSPO/Carbonic Anhydrase Modulator 1 (Compound 3) is a dual modulator for mitochondrial translocator protein and Carbonic Anhydrase with a K_i of 1.340 μM for TSPO and a K_A of 10.7 μM for CA VII. TSPO/Carbonic Anhydrase Modulator 1 promotes the production of neurosteroid, increases BDNF gene expression, exhibits neuroprotective efficacy .

HY-118397

RB394	PPAR	Others
RB394 is a potent dual sEH/PPARγ modulator isoform that promotes adipocyte browning and exhibits cardioprotective activity, and can be used to suppress metabolic syndrome.

HY-151963

PPARγ/GR modulator 1	PPAR Glucocorticoid Receptor	Metabolic Disease
PPARγ/GR modulator 1 is an orally active dual agonist of PPARγ and glucocorticoid receptor (GR), with K_is of 3.3 and 33.6 μM, respectively. PPARγ/GR modulator 1 can be used for the research of metabolic diseases, such as diabetes .

HY-152253

CB2R/FAAH modulator-2	FAAH Cannabinoid Receptor	Infection Neurological Disease Inflammation/Immunology Cancer
CB2R/FAAH modulator-2 (compound 26) is a dual targeting modulator that acts as a CB2R agonist and FAAH inhibitor. The K_i values for CB2R/FAAH modulator-2 are 10.8 and 152.9 nM for CB2R and CB1R, respectively, and the IC₅₀ value for FAAH is 6.2 μM. CB2R/FAAH modulator-2 can be used in studies related to cancer, deleterious inflammatory cascades occurring in neurodegenerative diseases, and COVID-19 infection .

HY-117965

Miricorilant CORT 118335	Glucocorticoid Receptor Mineralocorticoid Receptor	Endocrinology
Miricorilant (CORT 118335) is a dual selective glucocorticoid (GR) modulator/mineralocorticoid (MR) antagonist. Miricorilant can be used for the research of hypothalamic-pituitary-adrenal (HPA) axis related disorders .

HY-116273

ML299	Phospholipase	Cancer
ML299 is a selective allosteric modulator and a dual inhibitor of phospholipases D1 and D2 (IC₅₀ values are 6 and 12 nM, respectively). ML299 decreases invasive migration in U87-MG glioblastoma cells .

HY-149831

ZLY28	FXR	Metabolic Disease
ZLY28 is the first-in-class intestinal restricted and orally active FXR and FABP1 dual modulator. ZLY28 also is a novel anti-NASH agent. ZLY28 can be used for the research of nonalcoholic steatohepatitis (NASH) .

HY-P990706

Povetacicept ALPN-303	TNF Receptor	Inflammation/Immunology
Povetacicept (ALPN-303), an Fc fusion protein of an engineered TACI domain, is a dual APRIL/BAFF antagonist. Povetacicept modulates B lymphocytes and pathogenic autoantibodies for the study of Lupus and other B cell-related autoimmune diseases .

HY-128677

NCC007	Casein Kinase	Neurological Disease
NCC007 is a dual casein kinase Iα (CKIα) and δ (CKIδ) inhibitor with IC₅₀s of 1.8 and 3.6 μM, respectively. NCC007 can be used in research of modulating mammalian circadian rhythms .

HY-124478

Ethyl gentisate Ethyl 2,5-dihydroxybenzoate	Phosphatase	Metabolic Disease
Ethyl gentisate (Ethyl 2,5-dihydroxybenzoate) is a dual modulator for cell differentiation, that enhances the osteogenic differentiation of human mesenchymal stem cells (hMSCs) and alkaline phosphatase activity, inhibits RANKL-activated osteoclastogenesis in RAW264.7 cells, and balances the bone remodeling process .

HY-159484

Hsp110/sGC-modulator-1	HSP Guanylate Cyclase	Cardiovascular Disease
Hsp110/sGC-modulator-1 (compound 17i), an orally active Hsp110/sGC dual-target regulator, exhibits optimal Hsp110 and sGC molecular activities as well as remarkable cell malignant phenotypes inhibitory and vasodilatory effects. Hsp110/sGC-modulator-1 (compound 17i) attenuates pulmonary vascular remodeling and right ventricular hypertrophy via Hsp110 suppression .

HY-121736

AGI-12026 AGI-026	Isocitrate Dehydrogenase (IDH)	Neurological Disease
AGI-12026 is brain-penetrant dual inhibitor of mutant IDH1 and 2. AGI-12026 shows partial inhibition of the IDH1-R132H homodimer as allosteric modulators. AGI-12026 has the potential for research of glioma .

HY-163065

σ1 Receptor/μ Opioid receptor modulator 2	Opioid Receptor Sigma Receptor	Neurological Disease
σ1 Receptor/μ Opioid receptor modulator 2 (compound 4x) is a dual μOR agonist/σ1R antagonist, and displays picomolar μOR agonism activity (EC₅₀: 0.6 ± 0.2 nM) and good σ1R inhibitory activity (K_i: 363.7 ± 5.6 nM). σ1 Receptor/μ Opioid receptor modulator 2 exhibits robust analgesic effects in various pain models .

HY-155672

JPC0323	5-HT Receptor	Neurological Disease
JPC0323 is a dual 5-HT_2C/5-HT_2A receptor positive allosteric modulator. JPC0323 has on-target properties, acceptable plasma exposure and brain penetration. JPC0323 can be used for the research of neurological disease .

HY-158627

JPC0323 Oleate	5-HT Receptor	Others
JPC0323 Oleate is a derivative of JPC0323 (HY-155672). JPC0323 is a dual 5-HT_2C/5-HT_2A receptor positive allosteric modulator. JPC0323 has on-target properties, acceptable plasma exposure and brain penetration. JPC0323 can be used for the research of neurological disease .

HY-144501

D18	Toll-like Receptor (TLR) PD-1/PD-L1	Inflammation/Immunology Cancer
D18 is an immune modulator. D18 acts as a TLR7/8 dual agonist (EC₅₀=24 nM for hTLR7 and 10 nM for hTLR8, respectively). D18 increases PD-L1 expression through epigenetic regulation, thus sensitizing tumors to PD-1/PD-L1 blockade. D18 is a ADC cytotoxin uesd for the systhesis of ADC HE-S2 .

HY-117459

E-3030 free acid	PPAR	Metabolic Disease
E-3030 free acid is a potent dual activator of peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma, exhibiting significant antidiabetic and lipid-modulating effects. E-3030 decreases blood glucose, triglyceride, non-esterified fatty acids, and insulin levels, while increasing blood adiponectin levels. E-3030 improves glucose tolerance and shows remarkable triglyceride- and non-high-density lipoprotein cholesterol-lowering effects in animal models.

Cat. No.	Product Name	Target	Research Area

HY-P990706

Povetacicept ALPN-303	TNF Receptor	Inflammation/Immunology
Povetacicept (ALPN-303), an Fc fusion protein of an engineered TACI domain, is a dual APRIL/BAFF antagonist. Povetacicept modulates B lymphocytes and pathogenic autoantibodies for the study of Lupus and other B cell-related autoimmune diseases .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.